Discussion
Biocryst Pharmaceuticals‘ once-daily oral therapy Orladeyo (berotralstat) is now approved in Japan to prevent swelling attacks in children with hereditary angioedema (HAE) as young as 2 years old. Japan’s Ministry of Health, Labor and Welfare (MHLW) first approved Orladeyo in 2021 as a treatment for HAE…